Tags

Type your tag names separated by a space and hit enter

Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
Gynecol Oncol. 2001 May; 81(2):178-83.GO

Abstract

OBJECTIVES

Clear cell and serous carcinoma of the uterus are rare types of endometrial carcinomas. This study was designed to investigate the differential occurrence of apoptosis, Bcl-2, and Bax in endometrioid, clear cell, and serous carcinomas.

METHODS

In a total of 28 endometrial carcinomas as well as 4 samples of normal postmenopausal endometria, apoptotic changes were examined using molecular biochemical techniques. The expression of Bcl-2 and Bax proteins was also investigated by immunohistochemical staining with appropriate antibodies.

RESULTS

Labeling of DNA in situ indicated that apoptotic cells were sporadically seen in postmenopausal endometrium (5.2 +/- 2.1, n = 4). In contrast, cells undergoing apoptosis apparently were detected in endometrioid carcinoma (29.3 +/- 3.7, n = 20), and their numbers increased intensely in clear cell (49.5 +/- 5.6, n = 5) and serous carcinomas (50.8 +/- 6.0, n = 3). Autoradiographic analysis revealed that high-molecular-weight DNA was predominant in postmenopausal endometrium. However, a DNA ladder was identified in 7 of 10 carcinomas. Although Bcl-2 was immunonegative or faintly immunopositive in all cases, many cases of endometrioid carcinoma (43.6 +/- 4.1%, n = 20) were immunopositive for Bax, unlike postmenopausal endometrium (17.6 +/- 6.7%, n = 4). Moreover, the number of cells expressing Bax increased in clear cell (60.4 +/- 6.5%, n = 5) and serous carcinomas (66.8 +/- 7.6%, n = 3) compared with that in endometrioid carcinoma.

CONCLUSIONS

These results indicate that apoptosis occurs in a specific population of cells in different histologic components of endometrial carcinomas. The expression of Bax, but not of Bcl-2, might suggest histologic differentiation in endometrial carcinomas.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Wakayama Medical College, 811-1 Kimidera, Wakayama 641-0012, Japan. katsu@wakayama-med.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11330946

Citation

Kokawa, K, et al. "Apoptosis and the Expression of Bcl-2 and Bax in Patients With Endometrioid, Clear Cell, and Serous Carcinomas of the Uterine Endometrium." Gynecologic Oncology, vol. 81, no. 2, 2001, pp. 178-83.
Kokawa K, Shikone T, Otani T, et al. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium. Gynecol Oncol. 2001;81(2):178-83.
Kokawa, K., Shikone, T., Otani, T., Nishiyama, R., Ishii, Y., Yagi, S., & Yamoto, M. (2001). Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium. Gynecologic Oncology, 81(2), 178-83.
Kokawa K, et al. Apoptosis and the Expression of Bcl-2 and Bax in Patients With Endometrioid, Clear Cell, and Serous Carcinomas of the Uterine Endometrium. Gynecol Oncol. 2001;81(2):178-83. PubMed PMID: 11330946.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium. AU - Kokawa,K, AU - Shikone,T, AU - Otani,T, AU - Nishiyama,R, AU - Ishii,Y, AU - Yagi,S, AU - Yamoto,M, PY - 2001/5/2/pubmed PY - 2001/5/25/medline PY - 2001/5/2/entrez SP - 178 EP - 83 JF - Gynecologic oncology JO - Gynecol Oncol VL - 81 IS - 2 N2 - OBJECTIVES: Clear cell and serous carcinoma of the uterus are rare types of endometrial carcinomas. This study was designed to investigate the differential occurrence of apoptosis, Bcl-2, and Bax in endometrioid, clear cell, and serous carcinomas. METHODS: In a total of 28 endometrial carcinomas as well as 4 samples of normal postmenopausal endometria, apoptotic changes were examined using molecular biochemical techniques. The expression of Bcl-2 and Bax proteins was also investigated by immunohistochemical staining with appropriate antibodies. RESULTS: Labeling of DNA in situ indicated that apoptotic cells were sporadically seen in postmenopausal endometrium (5.2 +/- 2.1, n = 4). In contrast, cells undergoing apoptosis apparently were detected in endometrioid carcinoma (29.3 +/- 3.7, n = 20), and their numbers increased intensely in clear cell (49.5 +/- 5.6, n = 5) and serous carcinomas (50.8 +/- 6.0, n = 3). Autoradiographic analysis revealed that high-molecular-weight DNA was predominant in postmenopausal endometrium. However, a DNA ladder was identified in 7 of 10 carcinomas. Although Bcl-2 was immunonegative or faintly immunopositive in all cases, many cases of endometrioid carcinoma (43.6 +/- 4.1%, n = 20) were immunopositive for Bax, unlike postmenopausal endometrium (17.6 +/- 6.7%, n = 4). Moreover, the number of cells expressing Bax increased in clear cell (60.4 +/- 6.5%, n = 5) and serous carcinomas (66.8 +/- 7.6%, n = 3) compared with that in endometrioid carcinoma. CONCLUSIONS: These results indicate that apoptosis occurs in a specific population of cells in different histologic components of endometrial carcinomas. The expression of Bax, but not of Bcl-2, might suggest histologic differentiation in endometrial carcinomas. SN - 0090-8258 UR - https://www.unboundmedicine.com/medline/citation/11330946/Apoptosis_and_the_expression_of_Bcl_2_and_Bax_in_patients_with_endometrioid_clear_cell_and_serous_carcinomas_of_the_uterine_endometrium_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090-8258(01)96138-4 DB - PRIME DP - Unbound Medicine ER -